Establishment Labs (NASDAQ:ESTA) Director Quiros Juan Jose Chacon Sells 30,178 Shares

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 30,178 shares of the stock in a transaction on Friday, April 24th. The stock was sold at an average price of $65.78, for a total value of $1,985,108.84. Following the transaction, the director owned 1,109,684 shares of the company’s stock, valued at $72,995,013.52. The trade was a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, April 27th, Quiros Juan Jose Chacon sold 2,180 shares of Establishment Labs stock. The stock was sold at an average price of $66.26, for a total value of $144,446.80.
• On Thursday, April 23rd, Quiros Juan Jose Chacon sold 42,642 shares of Establishment Labs stock. The stock was sold at an average price of $65.43, for a total value of $2,790,066.06.
• On Tuesday, April 14th, Quiros Juan Jose Chacon sold 37,500 shares of Establishment Labs stock. The stock was sold at an average price of $65.23, for a total value of $2,446,125.00.
• On Wednesday, March 25th, Quiros Juan Jose Chacon sold 3,575 shares of Establishment Labs stock. The stock was sold at an average price of $60.08, for a total value of $214,786.00.
• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total value of $2,048,730.75.

Establishment Labs Stock Down 1.2%

ESTA stock opened at $65.47 on Tuesday. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04. The company has a market capitalization of $1.92 billion, a price-to-earnings ratio of -37.63 and a beta of 1.08. Establishment Labs Holdings Inc. has a fifty-two week low of $28.89 and a fifty-two week high of $83.31. The stock has a fifty day moving average of $66.15 and a 200-day moving average of $65.53.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.13. The company had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.19) EPS. As a group, equities research analysts predict that Establishment Labs Holdings Inc. will post -0.86 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on ESTA. Wall Street Zen cut Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Needham & Company LLC increased their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, February 24th. Canaccord Genuity Group raised their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Citigroup decreased their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. Finally, Stephens upped their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Establishment Labs currently has a consensus rating of “Moderate Buy” and an average price target of $86.86.

Hedge Funds Weigh In On Establishment Labs

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs in the 4th quarter worth $47,000. Quarry LP bought a new stake in shares of Establishment Labs during the 3rd quarter worth $34,000. State of Wyoming purchased a new position in Establishment Labs in the third quarter worth $71,000. MV Capital Management Inc. purchased a new position in Establishment Labs in the fourth quarter worth $146,000. Finally, Osaic Holdings Inc. increased its stake in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.